IBA Acquires ORA Group to Expand Nuclear Medicine Capabilities
December 19, 2025
Ion Beam Applications S.A. (IBA) has acquired ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC) to strengthen its leadership in nuclear medicine and radiochemistry. The cash-free, debt-free transaction (total consideration €15–20 million) is financed from IBA’s own funds and existing credit facilities and is immediately accretive to IBA Technologies’ revenue and EBITDA; ORA founder Vincent Tadino will continue with the combined business as CTO.
- Buyers
- IBA (Ion Beam Applications S.A.)
- Targets
- ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC)
- Industry
- Medical Devices
- Location
- Belgium
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eli Lilly Acquires Orna Therapeutics in Up to $2.4 Billion Deal
February 9, 2026
Biotechnology
Eli Lilly and Company has signed a definitive agreement to acquire Orna Therapeutics, valuing the deal at up to $2.4 billion. The acquisition is intended to expand Lilly’s genetic medicine and in vivo cell engineering capabilities, particularly for advancing in vivo CAR-T therapies using Orna’s circular RNA and lipid nanoparticle (LNP) platform.
-
Novartis Acquires Mariana Oncology
May 2, 2024
Biotechnology
Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.
-
IBA Acquires Radcal Corporation
February 9, 2024
Medical Devices
Belgium-based IBA (Ion Beam Applications S.A.) has signed an agreement to acquire all assets of Radcal Corporation, a California-based leader in diagnostic X‑ray measurement and dosimetry. The acquisition strengthens IBA's Medical Imaging Quality Assurance offering and expands its presence in the US; Radcal generated approximately USD 6 million in revenue in 2023 and employs about 35 people.
-
Isoray Completes Merger with Viewpoint Molecular Targeting
February 6, 2023
Biotechnology
Isoray, Inc. completed an all-stock merger with Viewpoint Molecular Targeting, effective February 3, 2023, combining Isoray's brachytherapy expertise with Viewpoint's radiopharmaceutical and diagnostic pipeline. Under the deal each Viewpoint share converted into 3.1642 shares of Isoray (totaling 136,545,075 shares, ~49% of Isoray's outstanding shares); Viewpoint CEO Thijs Spoor was named CEO of the combined company and outgoing Isoray CEO Lori Woods became Chair.
-
One Medical Acquires Iora Health
September 1, 2021
Healthcare Services
One Medical (1Life Healthcare, Inc.) completed the acquisition of Iora Health, a value-based primary care provider focused on Medicare populations. The deal expands One Medical's reach into senior and Medicare markets (Iora served ~39,000 patients as of July 31, 2021) and was executed via issuance/reservation of approximately 56 million One Medical shares.
-
Sotera Health Acquires Iotron Industries
August 3, 2020
Healthcare Services
Sotera Health has acquired Canadian-based Iotron Industries, expanding its electron beam (EBeam) sterilization footprint and adding Iotron's IMPELA accelerator expertise to its Sterigenics business. The acquisition brings Iotron's facilities in Indiana and British Columbia/Alberta into Sotera's global sterilization platform and strengthens Sterigenics' EBeam capabilities for medical device, pharmaceutical and industrial customers.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.